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DIRECT ADJUSTMENT METHOD ON AALEN’S ADDITIVE HAZARDS 
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by 
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ABSTRACT 
Aalen’s additive hazards model has gained increasing attention in recently years 
because it model all covariate effects as time-varying. In this thesis, our goal is to explore 
the application of Aalen’s model in assessing treatment effect at a given time point with 
varying covariate effects. First, based on Aalen’s model, we utilize the direct adjustment 
method to obtain the adjusted survival of a treatment and comparing two direct adjusted 
survivals, with univariate survival data.  Second, we focus on application of Aalen’s 
model in the setting of competing risks data, to assess treatment effect on a particular 
type of failure. The direct adjusted cumulative incidence curve is introduced. We further 
construct the confidence interval of the difference between two direct adjusted 
cumulative incidences, to compare two treatments on one risk.  
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CHAPTER I. INTRODUCTION 
The survival curves of different treatments are often presented in medical articles to 
visualize the efficacy of treatments. When the failure time data is obtained from a clinical trial, 
one can directly present the crude survival curve of each treatment group. When observational 
data is utilized, one needs to analyze data with appropriate regression model and compute the 
adjusted survival curve of a treatment based on the regression model.  
There are two methods to compute the adjusted survival curve of a treatment based on a 
regression model. The first method is known as the mean covariate method. For this method, one 
computes the survival probabilities for an individual with the average covariate values, given a 
treatment. Let  be the vector of average covariates. Let A denote treatment assignment, 
where . ) should be computed and viewed as the survival probability for 
treatment k. This method has the drawback that the covariate value for the average patient may 
be meaningless for categorical variables. For example, if the covariate gender is coded as 0 for 
male and 1 for female, it would be difficult to interpret the survival for an average patient the 
gender covariate value 0.7.  
The second method is the direct adjustment method, which computes the average survival 
curve over the entire sample, given a treatment (Makuch, 1982; Chang, Gelman and Pagano, 
1982; Gail and Byar, 1986). This method is also known as the group prognosis method. For a 
sample of size n, let Zi be the vector of characteristics for the ith individual. The direct adjusted 
survival curve is given by 

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 Z                               
Lee et al. (1992) and Ghali et al. (1986) provided the computer programs in SAS, STATA, and 
S-plus for obtaining the direct adjusted survival curves based on a Cox model (Cox,1972). The 
asymptotic results of the direct adjusted survival curves based on a Cox model and a Weibull 
regression model were studied by Gail and Byar (1986). Zhang et al. (2007) gave the asymptotic 
results of such curves based on a stratified Cox model and provided a SAS macro to derive the 
curves and their confidence limits. 
Cox model is the most commonly used regression model to assess covariate effect with 
failure time data. It is known that Cox model is a multiplicative hazards model, and the effect of 
covariate is multiplicative on the baseline level. Another principle framework to analyze failure 
time data is additive models, in which the hazard of a risk factor is often an additive increment 
on the baseline hazard. A nonparametric additive hazards model was proposed by Aalen (1989, 
1993). Aalen gave the least-square estimation of the regression coefficients. Huffer and 
McKeague (1991) proposed a weighted least-square estimation approach, which specifically 
addresses the problem of the unequal variances. Lin and Ying (1994) proposed an additive 
hazards model that assumes constant covariate effect. An additive hazards model that includes 
both time-varying effect and constant effect was studied by McKeague and Sasieni (1994).  
Aalen’s model has gained important attention in recent years because the effects of all 
covariates are modeled as time-varying (Martinussen and Scheike, 2006). Such a model does not 
require the constant proportional or additive hazards assumption between levels of a covariate, 
which is crucial for other regression models like Cox model or Lin and Ying’s model. In this 
thesis, we wish to explore the application of Aalen’s model in assessing treatment effect with 
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time-varying covariate effect. The aforementioned direct adjustment method shall be adopted to 
give adjusted treatment effect. Our first goal is to estimate direct adjusted survival of a treatment, 
and compare the direct adjusted survivals of two treatments at a given time. This has been 
implemented in a SAS macro and illustrated in stem cell transplant example.  
The second goal of this thesis is to illustrate the application of Aalen’s model with 
competing risks data. It has been pointed out that additive hazard model is consistent with the 
nature of competing risks data (Klein, 2005). It often appears in clinical articles that, with 
competing risks data, all cause-specific hazards and the all-cause hazard are specified as Cox 
models. Klein explicitly criticized this approach. Consider a study with two competing risks. Let 
z  and z  be cause-specific hazards. Let z be the hazard for the all-cause 
failure time. By definition, z  z  z . If one wishes to model all the above 
hazard rate functions by Cox models, that is,  
z z ,      
 z z ,      
 z z ,        
then one would expect the following relationship,  
z  z  z .    
Klein explained that the above equation holds only in some rare situations and the problem of 
internal inconsistency exists. Klein suggested additive hazard model for competing risks 
problems and specifically analyzed a real example with Aalen’s model as well as Lin and Ying’s 
model. In Klein’s paper, only the individual covariate adjusted cause-specific hazard and 
cumulative incidence function were presented.  
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In this thesis we apply the direct adjustment method to compute the cause-specific hazard 
and cumulative incidence function, on the basis of Aalen’s additive model. We give the 
confidence limits for the direct adjusted cause-specific hazard and cumulative incidence function 
for one type of failure. Treatment comparison regarding a given cause is implemented by 
constructing the confidence intervals of the difference between two direct adjusted cumulative 
incidence functions. We apply the methods to data of breast cancer patients from SEER registry. 
In this example, three competing risks exist: breast cancer, vascular disease, and other causes. 
The primary goal is to compare two treatments: breast conserving surgery and mastectomy. We 
wish to assess the effectiveness of treatments with respect to each type of failure and the all-
cause failure. 
The thesis is organized in the following way. Chapter 2 consists of three sections. In 
Section 2.1, we briefly review Aalen’s model. In Section 2.2, we give the asymptotic results for 
the direct adjusted survival curve based on Aalen’s model, and then describe the macro that 
reports the direct adjusted survival curves. In Section 2.3 we utilize the Aalen’s model to analyze 
competing risks data; we illustrate how to compare two treatments for a particular type of failure 
at a given time. The results from a simulation study are reported in Chapter 3. We analyze two 
real examples in Chapter 4 to illustrate the methods described in this thesis. The concluding 
remarks are given in Chapter 5. 
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CHAPTER II. METHODS 
 
2.1 The Additive Hazards Model 
Let T and C denote the failure time and the censoring time. For a sample of size n, the observed 
data can be summarized as  for , where  and 
, Zi is a p-dimensional vector of covariates with . Note 
that we have set the covariate vector as a row vector. Let be the counting process for the ith 
subject of the sample, where . Aalen’s model specify the intensity 
process of  as 
,   2.1 
where , is the at risk indicator, and  is a vector of 
regression coefficients. The integrated regression coefficient is given by  
.      2.2 
Aalen (1989) considered least-square estimation of B(t). Let  
and let  be a  matrix with the ith row given by 
.    2.3 
The Nelson-Aalen estimator of   is given by 
    d     2.4 
where          .     2.5 
and . 
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Define 
     .     2.6 
An estimator of the mean squared error function,  
,    2.7 
is given by  
diag d   2.8 
It is often desirable to predict the survival probability for an individual with given covariates. 
Given z, the cumulative hazard at t, , can be estimated by  
d .     2.9 
An estimator of survival probability is  
.    2.10 
For fixed z, variance of is given by , which can be estimated by  
2.2 The Direct Adjusted Survival Curves and the Macro 
Suppose that a study involves m treatments. We wish to estimate the overall survival for the ith 
treatment for i = 1, …, m. We can split the covariate vector Z in two components,  and , 
where  is the coding for treatment assignment and specifies patient’s characteristics. 
Specifically, Z = ( , . Please note that is fixed and  can be time-dependent. We further 
let X be the treatment index, corresponding to a specific coding of . For example, consider a 
study involving four treatments, we will let X  and treat the effect of treatment 1 as 

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baseline; X = 1 would be equivalent to , X = 2 would be equivalent to , 
and etc. We define  
i = 1, …, m,   2.12 
with the understanding that the value of X should be replaced by the corresponding value of . 
We further add a subscript l to z
i
 to let  be the characteristics of the lth patient. Let  
denote the direct adjusted survival of the ith treatment for i = 1, …, m, that is, 
.  can be estimated by 
     2.13                                    
Applying the delta method, we derive the variance of , which can be estimated by 
  2.14 
It is important to study the difference between two direct adjusted survivals, 
,                2.15 
It can be estimated by . The variance of can be estimated by 
  2.16 
We have implemented a SAS macro to compute the above estimators. Before we run the 
macro we should prepare a SAS data set to contain the following variables: a variable of the 

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failure time, a censoring indicator (which should be coded as 1 for an event occurs and 0 for 
censoring), a variable of treatment which should be coded as 1,…K, and the variables for 
patients’ characteristics. This SAS macro can be used for both continuous and categorical 
variables. An m-level categorical prognostic risk factor should be coded as (m-1) binary 
variables. For example, suppose that race is included in the regression and it contains four levels 
of White, Black, Hispanic and Other. We may treat White as the reference level and create three 
binary variables of Black (1 for Black, 0 otherwise), Hispanic (1 for Hispanic, 0 otherwise), and 
Other (1 for Other, 0 otherwise), for the race factor. 
Suppose that our macro is saved as a SAS file with the file name “estimate.sas”. One can 
save a copy of the file in the current working directory, and then use the following SAS 
statement to load the macro into the current program. 
% include ‘estimate.sas’ ; 
The macro will be invoked by running the following statement; 
% estimate (indata, time, event, group, option, covlist, outdata)   
where;   
 indata     the input SAS data set name  
 time      the variable of failure time  
 event        the variable of event indicator  
 group        the variable of treatment indicator 
 option        the variable of covariate indicator ( 1 with covariates, 0 without )   
 covlist        a list of all covariates 


 outdata      the SAS output data set name 
        The results of the macro will be saved in a SAS output data set named “outdata” and 
printed in the output window. The output data set includes the failure time variable, the estimated 
direct adjusted survivals and their estimated standard errors, as well as the estimated standard 
errors of the differences between two direct adjusted survivals. ’s and their estimated 
standard errors are given by “surv1, …, survK, se1, …, seK”. The estimated standard errors 
  for  are given by “se12, …, se ”. 
2.3 The Direct Adjusted Cause-Specific Hazards and Cumulative Incidence Functions 
In medical researches, the problems of competing risks often arise. For example, breast cancer 
patients usually have a relatively long-term post-surgery survival. Such patients may finally die 
from other causes instead of cancer. The survival of bone marrow transplant patients is another 
example of competing risks. Some patients die shortly after transplant due to graft-versus-host 
disease, and the other competing risk is leukemia relapse. For the problems of competing risks, 
the occurrence of one type of failure precludes other types of failure.  
It is known that, in the setting of competing risks, the cumulative incidence function is an 
important quantity to evaluate the cumulative failure probability due to a particular cause, with 
existence of other types of failure. In some applications, the cause-specific hazard has been 
utilized as well as criteria to compare effect of different groups. However, its drawback is 
obvious: the cause-specific hazard is meaningful in the hypothetical setting that other competing 
risks are removed. Therefore, in this thesis, we emphasize on the cumulative incidence function. 
For comparison, the result on cause-specific hazard is provided as well.  

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With covariates, the cumulative incidence function is defined as a function of all cause-
specific hazards, , where z) z) ) and z) is 
the cumulative hazard due to the kth cause for given covariate values z. Certain regression 
models needs to be specified for cause-specific hazards. It has been pointed out that the 
framework of additive hazards models is a solution to modeling the cause-specific hazards with 
the competing risks data (Klein, 2005). When effects of covariates are time-varying, Aalen’s 
model is the appropriate model. Let z be the row vector including 1, for intercept, and the 
covariate values. One needs to specify, 
z  z k   
The all-cause hazard should be the sum of all cause-specific hazards. Let   . 
Then, Aalen’s model can properly model the all-cause hazard, 
z  z  . 
Let  be the estimator of the regression function of the kth cause-specific hazard. A 
natural estimator of the regression function of the all-cause hazard would the sum of the 
estimators of the regression functions of all cause-specific hazards. The covariate adjusted 
cumulative hazard due to the kth cause is given by z) = z du. The overall survival 
can be estimated by z) z) ). 
In this thesis, we apply the direct adjustment method to give inference on assessing 
treatment effect with respect to a specific type of failure. Suppose that K types of failure exist. In 
order to simply the notations, we consider two treatments only, but the results can be easily 

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extended to a setting with more than two treatments. Let X indicates the treatment group index, 
where . We define       
   2.17 
Let Aik(t) be the direct adjusted cumulative hazard of the ith treatment for the kth type of failure. 
It can be estimated by 
    2.18 
Let  be the difference in the adjusted cumulative hazard between two treatments for the kth 
type of failure, 
                           2.19 
Variances of  and  can be estimated by 
   2.20 
           2.21 
We define to be the cumulative incidence function of treatment i for the kth type of failure. 
The direct adjusted estimator of 
  2.22 
Its variance can be estimated by 


 2.23 
where  
   2.24
    2.25
The difference of cumulative incidence functions between two treatments is often of 
study interest. Let  Obviously,  We have derived 
the variance formula of . The estimated variance is given by 
  2.26 
where 
    2.27 
     2.28 

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CHAPTER III. SIMULATION STUDY 
The settings considered in the simulation study include two treatments (1 and 2). Both 
discrete and continuous covariates have been simulated in the study. Treatment assignment was 
determined by generating a Bernoulli random variable with the probability 0.5 to be assigned to 
treatment 1, and the probability 0.5 to be assigned to treatment 2.   
First, we conducted simulation on settings with discrete covariates. We let treatment 1 be 
the better treatment option with the baseline cumulative hazard 0.1t, an term should be 
added to the cumulative hazard if the observation is in treatment 2 group. Three covariates, , 
and  were generated from Bernoulli distributions with the probability 0.5 to take the value 
1. Given t, the cumulative hazard will be increased by 0.05t, , if , or  takes the 
value 1, respectively.  
In summary, given z, the cumulative hazard with treatment 1 is  
        ,    3.1 
and the cumulative hazard with treatment 2 is 
.   3.2 
Utilizing the relation , we applied the inverse transform method to 
generate failure time T. First, a random unit, U, needs to be generated. Then the failure time T, 
given treatment 1, shall be obtained by the following formulas with various values of z, 
i. , , 
ii. , , 
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iii. , , 
iv. , , 
v. , , 
vi. , , 
vii. , , 
viii. ,  
Given treatment 2, the failure time can be generated by the following formulas, 
i. ,   , 
ii. , , 
iii. , , 
iv. ,     , 
v. , , 

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vi. ,   , 
vii. ,   , 
viii. ,     
 The censoring time was generated from the Uniform distribution [0, a]. The value of a 
was chosen to yield the censoring rates 25% and 50%. We considered sample size 100 and 200, 
1000 replicates were simulated for each setting. The simulation results are shown in Table 1 and 
Table 2. In the tables, we report the difference between the average of the estimated directed 
survival probabilities and the true values, the empirical standard errors, the averages of the 
estimated standard errors, and the 95% coverage. For 95% coverage, we computed three types of 
confidence intervals. They are linear, log-log transformed and arcsine-square-root transformed 
confidence intervals.  
For the second set of simulation, we considered continuous covariates. We still let 
treatment 1 be the better treatment option with the baseline cumulative hazard , the cumulative 
hazard for treatment 2 was set to be  higher. The covariates , and  were generated 
from a standard Normal distribution. We further set, given z, the cumulative hazard with 
treatment 1 is  
,    3.3 
and the cumulative hazard with treatment 2 is 
.    3.4 

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The failure time was generated using the inverse transform method. First, generate a random 
unit, U. The failure time T, given treatment 1, is obtained by 
. 
Given treatment 2, the failure time can be generated by  
. 
 The censoring time was generated from the Uniform distribution [0, a]. We simulated 
settings with the censoring rates 25%, 50%, and the sample size 100, 200. 1000 replicates were 
utilized. The simulation results are shown in Table 3 and Table 4.  
According to Table 1-4, the average estimated standard errors are quite close to the 
empirical standard errors when the regression model contains only continuous covariates, but 
they are slightly smaller than the empirical standard errors for models with discrete covariates. 
Through all settings, the log-log transformed confidence interval consistently performs better 
than the linear or arcsine-square-root transformed confidence interval, and should be strongly 
recommended.  

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Table 1: Simulation results for discrete covariates with censoring rate 25% 
 
t  0.75  1  1.25  1.5  1.75  2.0 
 
n = 100    
 
 
 
Bias  0.005  0.008          0.013          0.016          0.017  0.021 
Empirical SE 0.056           0.065           0.071          0.075          0.077  0.074 
Estimated SE 0.053          0.061           0.067            0.071         0.072  0.072 
Linear-Cov.  0.901          0.920          0.918         0.908           0.919  0.927 
LogLog-Cov.  0.962      0.955      0.951      0.936      0.936  0.944 
Arcsin-Cov. 0.929      0.937      0.930      0.917      0.926  0.931 
 
 
 
Bias  0.006           0.008          0.010          0.012           0.012  0.017 
Empirical SE 0.056          0.065          0.073          0.074          0.077  0.077 
Estimated SE 0.055          0.064          0.069          0.072          0.072  0.072 
Linear-Cov. 0.928          0.925         0.916           0.929          0.922  0.921 
LogLog-Cov. 0.963  0.954  0.947  0.949  0.939  0.938 
Arcsin-Cov. 0.943      0.941      0.925      0.936      0.926  0.925 
 
n = 200   
 
 
 
Bias  0.003      0.005      0.007      0.008      0.008  0.010
Empirical SE 0.039      0.045      0.050      0.052      0.052  0.052 
Estimated SE 0.038      0.044      0.048      0.050      0.051  0.051 
Linear-Cov.  0.926      0.938      0.932      0.931      0.935  0.934
LogLog-Cov.  0.959      0.949      0.947      0.951      0.948  0.945  
Arcsin-Cov. 0.948      0.948      0.936      0.939      0.936  0.937 
 
 
 
Bias  0.004      0.004      0.006      0.007      0.007  0.006
Empirical SE 0.041      0.048      0.050      0.053      0.054  0.054 
Estimated SE 0.039      0.045      0.049      0.051      0.051  0.050 
Linear-Cov. 0.920      0.937      0.947      0.939      0.929  0.928 
LogLog-Cov.  0.956      0.954      0.965      0.955      0.937  0.934 
Arcsin-Cov. 0.934      0.948      0.954      0.942      0.935  0.930 
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Table 2: Simulation results for discrete covariates with censoring rate 50% 
 
t  0.75  1  1.25  1.5  1.75  2.0 
 
n = 100    
 
 
 
Bias  0.006  0.010          0.015          0.020          0.023  0.030 
Empirical SE 0.058           0.068           0.077          0.083          0.088  0.091 
Estimated SE 0.055          0.065           0.073            0.078         0.083  0.086 
Linear-Cov.  0.908          0.925          0.917         0.913           0.922  0.919 
LogLog-Cov.  0.958      0.954      0.949      0.941      0.951  0.940 
Arcsin-Cov. 0.928      0.938      0.931      0.921      0.934  0.925 
 
 
 
Bias  0.006           0.009          0.012          0.016           0.019  0.025 
Empirical SE 0.058          0.070          0.079          0.081          0.086  0.092 
Estimated SE 0.057          0.067          0.074          0.079          0.082  0.085 
Linear-Cov. 0.925          0.919         0.915           0.931          0.929  0.923 
LogLog-Cov. 0.962  0.948  0.948  0.941  0.948  0.939 
Arcsin-Cov. 0.948      0.941      0.932      0.953      0.934  0.925 
 
n = 200   
 
 
 
Bias  0.003      0.006      0.007      0.008      0.011  0.014
Empirical SE 0.041      0.048      0.054      0.058      0.059  0.062 
Estimated SE 0.039      0.047      0.052      0.056      0.058  0.059 
Linear-Cov.  0.931      0.929      0.926      0.927      0.934  0.932
LogLog-Cov.  0.956      0.952      0.943      0.940      0.947  0.947  
Arcsin-Cov. 0.946      0.935      0.931      0.933      0.936  0.936 
 
 
 
Bias  0.005      0.005      0.007      0.008      0.009  0.009
Empirical SE 0.043      0.050      0.054      0.060      0.061  0.062 
Estimated SE 0.041      0.048      0.053      0.056      0.058  0.059 
Linear-Cov. 0.928      0.938      0.945      0.931      0.932  0.922 
LogLog-Cov.  0.945      0.950      0.956      0.939      0.945  0.928 
Arcsin-Cov. 0.938      0.948      0.952      0.937      0.938  0.925 
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Table 3: Simulation results for continuous covariates with censoring rate 25% 
 
t   0.2  0.4  0.6  0.8  1.0 
 
n = 100  
 
 
 
Bias   -0.008      0.001      0.011      0.018      0.024
Empirical SE  0.067      0.051      0.066      0.077      0.080 
Estimated SE  0.026      0.050      0.067      0.077      0.081 
Linear-Coverage  0.885      0.930      0.935      0.931      0.939 
LogLog-Coverage 0.848     0.960      0.959      0.946      0.956 
Arcsin-Coverage 0.922      0.948      0.949      0.942      0.942 
 

 
Bias   -0.008      0.003      0.010      0.016      0.022 
Empirical SE  0.068      0.056      0.071      0.078      0.075 
Estimated SE  0.031      0.057      0.072      0.076      0.073 
Linear-Coverage 0.919      0.938      0.944      0.936      0.921 
LogLog-Coverage  0.893      0.970      0.971      0.949      0.932 
Arcsin-Coverage 0.937      0.956      0.956      0.939      0.928 
 
n = 200 
 
 
 
Bias   -0.006     -0.003      0.000      0.004      0.009 
Empirical SE  0.021      0.037      0.049      0.054      0.056
Estimated SE  0.020      0.036      0.048      0.054      0.055 
Linear-Coverage 0.918      0.936      0.935      0.944      0.945 
LogLog-Coverage  0.920      0.944      0.947      0.951      0.956 
Arcsin-Coverage 0.952      0.945      0.944      0.947      0.946 
 

 
Bias   -0.002      0.001      0.003      0.008      0.008 
Empirical SE  0.023      0.041      0.052      0.055      0.053 
Estimated SE  0.022      0.041      0.051      0.054      0.050 
Linear-Coverage 0.916      0.948      0.934      0.945      0.933  
LogLog-Coverage  0.958      0.955      0.941      0.953      0.941 
Arcsin-Coverage 0.938      0.951      0.938      0.948      0.933 
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Table 4: Simulation results for continuous covariates with censoring rate 50% 
 
t   0.2  0.4  0.6  0.8  1.0 
 
n = 100 
 
 
 
Bias   -0.008      0.001      0.013      0.024      0.047
Empirical SE  0.067      0.053      0.072      0.089      0.113
Estimated SE  0.027      0.053      0.073      0.088      0.113 
Linear-Coverage 0.880      0.932      0.926      0.923      0.920 
LogLog-Coverage  0.840      0.962     0.969      0.944      0.948 
Arcsin-Coverage 0.919      0.946      0.946      0.935      0.926 
 

 
Bias   -0.008      0.003      0.013      0.020      0.037 
Empirical SE  0.068      0.059      0.078      0.090      0.101 
Estimated SE  0.032      0.059      0.078      0.087      0.097 
Linear-Coverage 0.911      0.925      0.943      0.928      0.933 
LogLog-Coverage  0.891      0.967      0.962      0.950      0.946 
Arcsin-Coverage 0.935      0.951      0.952      0.933      0.939 

n = 200 
 

 
Bias   -0.005     -0.002      0.002      0.007      0.016      
Empirical SE  0.022      0.038      0.052      0.061      0.067
Estimated SE  0.020      0.038      0.052      0.061      0.068 
Linear-Coverage  0.912      0.941      0.947      0.941      0.948 
LogLog-Coverage  0.918      0.953      0.962      0.959      0.960 
Arcsin-Coverage 0.950      0.949      0.956      0.948      0.954 
 
 
 
Bias   -0.002      0.001      0.005      0.011      0.016 
Empirical SE  0.023      0.043      0.057      0.062      0.064  
Estimated SE  0.023      0.043      0.055      0.061      0.062 
Linear-Coverage 0.913      0.936      0.923      0.935      0.931 
LogLog-Coverage 0.964      0.956      0.939      0.946      0.937 
Arcsin-Coverage 0.948      0.946      0.928      0.944      0.930 
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CHAPTER IV. EXAMPLES 
4.1 Example 1 
The goal of study is to compare three types of stem cell transplantation in treating follicular 
lymphoma patients. The study cohort consists of 904 follicular lymphoma patients who received 
either allogeneic or autologous transplant between 1990 and 1999 and reported to the 
International Bone Marrow Transplant Registry. Among these 904 patients, 176 received 
allogeneic transplant, 131 received purged autologous transplant, and 597 received unpurged 
autologous transplants. The median follow up times for survivors are 36, 49 and 41 months for 
allogeneic, purged autologous and unpurged autologous transplant recipients. Distribution of risk 
factors in three transplant groups is shown in Table 5. It seems that that the purged autologous 
transplant group contained more healthy patients than the other two groups. In the purge 
autologous group, relatively more patients had high Karnofsky scores (87%) and were in the 
early stage of disease (53%). Differences in patients’ baseline profiles between transplant groups 
need to be adjusted when one compares three types of transplantation. This data set was 
originally analyzed by Besien et al. (2003). Because the hazards between transplant groups are 
apparently nonproportional, Besien et al. considered a Cox model stratified on transplant groups. 
Aalen’s model gives more flexibility on modeling covariate effects. We wish to reanalyze the 
data set and we are interested in comparison in the survival between transplant groups at 3-year 
and 5-year after transplant. 
 The macro described in Section 2.2 was applied to give us the comparison results. First, 
we made a SAS data set that included the following variables: “time”=failure time; 
“death”=death indicator; “transplant”=1 for unpurged auto transplant, 2 for purged auto 
transplant, 3 for allogeneric transplant; “stage”=1 if disease is in advanced stage, 0 otherwise; 
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“chemo1”=1 if chemosensitivity is resistant; “chemo2”=1 if chemosensitivity is untreated / 
unknown, 0 otherwise; “LHD1”=1 if LHD is abnormal; “LHD2”=1 if LHD is unknown; 
“kscore”=1 if Karnofsky is 90%- 100%; “DX2T1”=1 if interval from diagnosis is 1-2 years; 
“DX2T2”=1 if interval from diagnosis is more than 2 years; and “age”=1 if older than 40; 
“year1”=1 if year of diagnosis  between 1994-1996 ; “year2”=1 if year of diagnosis greater or 
equal to 1997. The macro was loaded by %include statement and invoked by  
%estimate (data, time, event, group, stage chemo1 chemo2 LHD1 LHD2 kscore DX2T1 
DX2T2 age year1 year2 , out). 
The direct adjusted survival curves of three types of transplant have been plotted in 
Figure 1. In the figure, two autologous transplants yield better survival outcome than allogeneic 
transplant, during the majority study period. Among two autologous transplants, they have 
similar survival outcome within 1 year post transplant, while purged transplant give higher 
survival rate after 1 year. Figure 2-4 shows the differences between any two transplants and their 
confidence intervals. These figures suggest obvious changes in treatment effect over time.  
We further select the time points, 3 year and 5 year, to assess effects of transplants. 
Comparison of survival rates between any two transplants, at the given time points, is given in 
Table 6. At both time points, unpurged autologous transplant yields lower survival probabilities 
than purged autologous transplant. However, the effect is only marginally significant (p-values: 
0.1075 and 0.0869, respectively). Compared to allogeneic transplant, two autologous transplants 
have significant better result in terms of three-year survival rate (p-values: 0.0087 and 0.0019, 
respectively). Two autologous transplant still outperform allogeneic transplant in terms of five 
year survival rate (p-values: 0.0694 and 0.0465, respectively), however, the magnitude has been 
reduced.  
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Table 5:   Groups and risk factors for transplantation of follicular lymphoma patients__  
 
 
    _Unpurged   Purged   Allogeneic____ 
 
Total    597   131    176  
 
Stage 
 
Early    350  (59%)  69  (53%)  85 (48%) 
Advanced   247  (41%)  62  (47%)  91 (52%) 
 
Chemosensitivity 
 
Sensitivity   488  (82%)  111  (85%)  118 (67%) 
Resistant   66  (11%)  14  (11%)  31 (18%) 
Untreated/unknown  43   (7%)  6 (4%)  27 (15%) 
     
LHD 
 
Normal    389  (65%)  55  (42%)  117 (67%) 
Abnormal   174  (29%)  27  (21%)  44 (25%) 
Unknown   34 (6%)  49 (37%)  15 (8%)  
 
Karnofsky score 
 
No more than 80%  183  (31%)  17  (13%)  60 (34%) 
90%-100%   414  (69%)  114  (87%)  116 (66%) 
 
Interval from diagnosis 
 
Less than 1 yr   115  (19%)  27  (21%)  26 (15%) 
1-2 yrs    156  (16%)  32  (24%)  56 (32%) 
More than 2 yrs   326 (55%)  72 (55%)  94 (53%) 
 
Age group 
 
No older than 40  100  (17%)  22  (17%)  77 (44%) 
Older than 40   497  (83%)  109  (83%)  99 (56%) 
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Table 6:  Direct adjusted survivals of unpurged-auto (S1), purged-auto (S2) and allogenic (S3)__ 
 
 
___________ S1  SE  S2  SE  S3  SE 
 
 
36 months 0.651  0.020  0.708  0.041  0.546  0.038    
60 months 0.550  0.025  0.626  0.049  0.517  0.042 
 
 _____  S1-S2  SE(S1-S2) p-value 
 
36 months -0.057  0.046  0.1075 
 
60 months -0.075  0.055  0.0869 
   
 
                        S1-S3  SE(S1-S3) p-value 
36 months  0.105  0.044  0.0087 
60 months  0.033  0.049  0.0694 
   
 

_________ S2-S3  SE(S2-S3) p-value 
36 months  0.162  0.056  0.0019 
60 months  0.108  0.064  0.0465 
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4.2 Example 2
In this study, we would compare the direct adjusted cumulative incidence probabilities between 
two treatment options (mastectomy vs. breast conserving surgery) for early staged breast cancer 
patients. The study cohort was selected from the published SEER cancer case registry. The 
Surveillance, Epidemiology, and End Results (SEER) program collects all cancer cases 
occurring in the participating SEER sites and periodically publish the database to give source to 
clinicians and epidemiologist who conduct various cancer-related research projects. The SEER 
registry was initiated in 1973 with 9 sites and has now been expanded to 13 sites, covering 26% 
of the US population. In our study, female breast cancer cases were selected if a patient was 
diagnosed with stage I/II breast cancer between 1991 and 1996, resided in Atlanta at diagnosis, 
was 30-79 years of age at time of diagnosis, and her breast cancer was the first malignant 
primary cancer and was microscopically confirmed, and either mastectomy or breast conserving 
surgery (BCS) was conducted. A total of 3760 patients entered the study cohort. The cut-off date 
for the database used in this study is December 31, 2002. Most of the patients were followed till 
this date, but a small percentage of patients were lost to follow-up before this date. The median 
follow up time is 92 months. During the follow-up, 929 deaths were recorded: 598 died from 
breast cancer, 162 died from vascular disease and 169 died from other causes. 
 In this example, three competing risks exist: breast cancer, vascular disease and other 
cause. Mastectomy and BCS are the surgical procedures that patients received. Mastectomy is 
the surgical procedure of removing the affected breast. BCS (or lumpectomy) is to remove only 
the lump (tumor), which is considered to be non-invasive compared to mastectomy.Prognostic 
factors that we identified from SEER database include demographical characteristics, patient’s 
age at diagnosis and race, and tumor-related characteristics, tumor size, lymph node status, tumor 
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grade and extension. Table 7 shows the distribution of the risk factors in two treatment groups. It 
is obvious that the distribution of tumor-related factors is very different between two groups, the 
cohort receiving mastectomy have much worse profiles than the cohort receiving BCS. It should 
be important to address the problem of the imbalance in distribution of tumor-related factors 
when comparing these two surgical procedures.  
When fitting Aalen’s models on all cause-specific hazards, we include the following  
factors:  race (White, Black and Other), age at diagnosis (30-49, 50-64 and 65-79), tumor size  (< 
2 cm, 2-5 cm and > 5 cm), lymph node status ( negative, positive and unknown/unexamined), 
tumor grade (1, 2 and  3 / 4), tumor extension (confined and invasive).  
 The results are given for the predetermined time points, 5 years and 8 years. Figures 5, 7 
and 9 give the direct adjusted cumulative incidence curves for both types of surgery on cancer, 
vascular disease, and other cause, respectively. Differences between two direct adjusted 
cumulative incidence curves and their 95% confidence intervals, for all competing risks, are 
given in Figures 6, 8 and 10. Figure 5 and 6 show that mastectomy and BCS have similar 
outcome on cancer. Figure 7-10 show that mastectomy has higher cumulative incidence than 
BCS for vascular disease and other cause, but the effect is only marginally significant at the 
selected times points. Direct adjusted cumulative incidence estimates and their estimated 
standard errors, as well as the results on treatment comparison at the selected times points are 
given in Table 8. Finally, we give the results on direct adjusted cumulative cause-specific 
hazards in Figures 11-14.. It is interesting that treatment effect is significant with respect to 
direct adjusted cause-specific hazard, but insignificant or marginal significant with respect to 
direct adjusted cumulative incidences. Because of the drawback of cause-specific hazard in the 
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setting of competing risks, the results on the direct adjusted cumulative incidences are 
recommended. 
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Table 7:   Causes, treatments and risk factors for breast cancer patients    
 
 
    _Mastectomy       BCS____ 
 
Total    2020 (53.7%) 1740  (46.3%) 
 
Cause 
Censored   1422  (70.4%) 1409  (81%) 
Cancer    386  (19.1%) 212  (12.2%) 
Vascular Disease  107  (5.3%)  55  (3.1%) 
Other    105  (5.2%)  64  (3.7%) 
 
 
Age groups 
30-49    717  (35.5%) 650  (37.3%) 
50-64    691  (34.2%) 673  (38.7%) 
65-79    612  (30.3%) 417  (24.0%) 
 
Race 
White    1480  (73.3%) 1315  (75.6%) 
Black    485  (24%)  383  (22%) 
Other    55  (2.7%)  42  (2.4%) 
 
Size group 
<2 cm    917  (45.4%) 1190  (68.4%) 
2-5 cm    1070  (53.0%) 546  (31.4%) 
>5 cm    33  (1.6%)  4  (0.2%) 
 
Node 
Negative   1194  (59.1%) 1208  (69.4%) 
Positive   783  (38.7%) 417  (23.9%) 
Unknown/Unexamined  43  (2.1%)  115  (6.6%) 
 
Grade 
1    220  (10.9%) 346  (19.9%) 
2    839  (41.5%) 722  (41.5%) 
3 /4    961  (47.6%) 672  (38.6%) 
 
Ext 
Confined   1932  (95.6%) 1721  (98.9%)    
Invasive   88  (4.4%)  19  (1.1%) 
 
Diagnosis Year 
1991    331  (16.4%) 177  (10.2%) 
1992    344  (17.0%) 207  (11.9%) 
1993    336  (16.6%) 276  (15.9%) 
1994    327  (16.2%) 302  (17.3%) 
1995    352  (17.4%) 353  (20.3%) 
1996    330  (16.3%) 425  (24.4%) 
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Table 8:  Direct adjusted cumulative incidence functions for breast cancer patients 
 
 
 
Cause  CIF1  SE  CIF2  SE   
 
Cancer         
60 months 0.102  0.006  0.101  0.007   
96 months 0.153  0.008  0.146  0.008   
Vascular Disease 
60 months 0.021  0.003  0.015   0.002   
96 months 0.043  0.004  0.032  0.004   
Other 
60 months 0.028  0.003  0.019  0.003   
96 months 0.047  0.004  0.036  0.004   
 
Cause  (CIF1-CIF2)   SE(CIF1-CIF2)  p-value  
 
Cancer         
60 months 0.001   0.009   0.456 
96 months 0.007   0.012   0.281 
Vascular Disease 
60 months 0.006   0.004   0.067 
96 months 0.011   0.007   0.058 
Other 
60 months 0.009   0.005   0.036 
96 months 0.011   0.007   0.058 
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CHAPTER V. CONCLUSION
In this thesis, our goal is to explore the application of Aalen’s additive hazards model in 
analyzing failure time data. Analytical methods implemented in the thesis were motivated by the 
advantages of Aalen’s model: 1. Aalen’s model can naturally model influence of a risk factor 
that changes over time, and does not require constant multiplicative or additive effect assumption 
for the results to be meaningful. 2. With competing risks data, Aalen’s model can be utilized to 
model all cause-specific hazards, and an additive model still holds for the all-cause hazard.  
Based on Aalen’s model, we have adopted the direct adjustment method to make a 
survival curve of a treatment. The direct adjustment method fits Aalen’s model very well. The 
relevant direct adjusted survival curves of different treatments do not need to follow certain 
patterns required by the parametric or semi-parametric models. This is clearly illustrated by the 
stem cell transplant example given in Section 4.1. We have plotted the direct adjusted survival 
curves of three types of transplant in Figure 1. The curve of allogeneic transplant is very 
different from the curves of the other two types of transplant within the first three years. 
However, all three curves become close after five years. Treatment comparison at a given time 
point have been implemented by making a confidence interval for the difference between two 
direct adjusted survival probabilities. In the stem cell transplant example, we have illustrated that 
the magnitude of treatment effect changes at different time points.  
With competing risks data, we suggest to fit Aalen’s model for each cause-specific 
hazard, and the all-cause hazard, which is the sum of all cause-specific hazard, can be time-
varying. Direct adjustment has been also adopted to make the cumulative incidence curve of a 
treatment, due to one type of failure. Treatment effect at a time, on one type of failure, has been 
assessed by comparing two direct adjusted cumulative incidence probabilities. In the breast 
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cancer example, we have compared the survival outcome of two types of surgery, mastectomy 
versus BCS, with respect to three types of failures, cancer, vascular disease, and other cause. 
Figures 5 to 10 show that mastectomy yields higher cumulative failures than BCS due to 
vascular disease or other cause for the majority of the time, while these two types of surgery are 
quite similar in terms of cancer failures. For comparison, we have made the direct adjusted 
cumulative hazards of different treatments. The cumulative hazard of a treatment on one type of 
failure is meaningful only if one hypothetically removes other competing risks.  
In this thesis, we have illustrated flexibility of Aalen’s model in analyzing failure time 
data, especially in the context of competing risks. Compared to the commonly used semi-
parametric models like Cox (1972) or Lin and Ying’s additive model (1994), the power is 
reduced with Aalen’s model to compensate for the complete time-varying effect of all covariates. 
Various graphical diagnoses have been proposed to show the goodness of fit of a semi-
parametric model. It is interesting to further investigate whether a certain criterion can be 
developed to direct one to adopt a much simple model like Cox or Lin and Ying’s model.  
Estimation of Aalen’s model has been improved by Huffer and McKeague (1991). They 
proposed a weight least square estimator, which has been show to be more efficient. An 
extension of current work is to adopt the estimation approach given by Huffer and McKeague. 
Another important application is to develop robust inference approach to adjust for random 
effect, also known as frailty, which often appear in failure time data. 
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